Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ASP7517 |
Trade Name | |
Synonyms | ASP 7517|ASP-7517 |
Drug Descriptions |
ASP7517 comprises artificial adjuvant vector cells engineered to express CD1d, which are loaded with the Wilms' tumor 1 (WT1) antigen and the CD1d ligand alpha-galactosylceramide on the cell surface, which may result in the activation of antitumor immune response against tumor cells expressing WT1 (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C169049 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ASP7517 | ASP7517 | 0 | 2 |
ASP7517 + Pembrolizumab | ASP7517 Pembrolizumab | 0 | 1 |